APOBEC3A

Across TCGA pan-cancer cohorts, APOBEC3A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APOBEC3A data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher APOBEC3A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated APOBEC3A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where APOBEC3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.942	0.719	.012	22	view →
LUAD	DFS	Quartile	All	0.818	1.000	.010	19	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.858	.008	10	view →
PDAC	OS	Median	All	0.259	0.664	.014	10	view →
UCEC	OS	Tertile	II,III,IV	1.000	0.476	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APOBEC3A–HNSC (OS)

Open the HNSC breakdown →